These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 12070358)

  • 21. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
    Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
    Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Achieving continuous manufacturing for final dosage formation: challenges and how to meet them. May 20-21, 2014 Continuous Manufacturing Symposium.
    Byrn S; Futran M; Thomas H; Jayjock E; Maron N; Meyer RF; Myerson AS; Thien MP; Trout BL
    J Pharm Sci; 2015 Mar; 104(3):792-802. PubMed ID: 25501530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How academia and the pharmaceutical industry can work together: the president's lecture, annual meeting of the American Thoracic Society, San Francisco, California.
    Rosenblatt M
    Ann Am Thorac Soc; 2013 Feb; 10(1):31-8. PubMed ID: 23509330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current models, challenges and best practices for work conducted between European academic cooperative groups and industry.
    Stahel RA; Lacombe D; Cardoso F; Casali PG; Negrouk A; Marais R; Hiltbrunner A; Vyas M;
    ESMO Open; 2020 Mar; 5(2):. PubMed ID: 32213534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design of comprehensive Alzheimer's disease centers to address unmet national needs.
    Trojanowski JQ; Arnold SE; Karlawish JH; Brunden K; Cary M; Davatzikos C; Detre J; Gaulton G; Grossman M; Hurtig H; Jedrziewski K; McCluskey L; Naylor M; Polsky D; Schellenberg GD; Siderowf A; Shaw LM; Van Deerlin V; Wang LS; Werner R; Xie SX; Lee VM
    Alzheimers Dement; 2010 Mar; 6(2):150-5. PubMed ID: 20298979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Driving drug discovery: the fundamental role of academic labs.
    Silber BM
    Sci Transl Med; 2010 May; 2(30):30cm16. PubMed ID: 20445199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Academic technology transfer and radiology: a strong partnership for the future.
    Eusemann CD; Sammons BE; Holmes DR; Brady TJ; Erenburg I; Toneguzzo F
    Acad Radiol; 2007 Nov; 14(11):1289-95. PubMed ID: 17964453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of academic institutions in the development of drugs for rare and neglected diseases.
    Coles LD; Cloyd JC
    Clin Pharmacol Ther; 2012 Aug; 92(2):193-202. PubMed ID: 22760003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alcohol medications development: advantages and caveats of government/academia collaborating with the pharmaceutical industry.
    Litten RZ; Ryan M; Falk D; Fertig J
    Alcohol Clin Exp Res; 2014 May; 38(5):1196-9. PubMed ID: 24689461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibiotic resistance--action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005.
    Finch R; Hunter PA
    J Antimicrob Chemother; 2006 Sep; 58 Suppl 1():i3-i22. PubMed ID: 17003063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Forum on the future of academic medicine: session IV--the realities of the health care environment.
    Iglehart J
    Acad Med; 1998 Sep; 73(9):956-61. PubMed ID: 9759097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergence of Chinese drug discovery research: impact of hit and lead identification.
    Zhou C; Zhou Y; Wang J; Zhu Y; Deng J; Wang MW
    J Biomol Screen; 2015 Mar; 20(3):318-29. PubMed ID: 25520370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Challenges in drug development for muscle disease: a stakeholders' meeting.
    Mendell JR; Csimma C; McDonald CM; Escolar DM; Janis S; Porter JD; Hesterlee SE; Howell RR
    Muscle Nerve; 2007 Jan; 35(1):8-16. PubMed ID: 17068768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Academic-Pharma drug discovery alliances: seeking ways to eliminate the valley of death.
    Hammonds T
    Future Med Chem; 2015; 7(14):1891-9. PubMed ID: 26393391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Models and modeling systems in Alzheimer disease drug discovery.
    Khachaturian ZS
    Alzheimer Dis Assoc Disord; 2002; 16 Suppl 1():S9-S12. PubMed ID: 12070356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Academia-industry partnerships in drug discovery.
    Dalrymple M; Taylor D; Kettleborough C; Bryans J; Solari R
    Expert Opin Drug Discov; 2006 Jun; 1(1):1-6. PubMed ID: 23506026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Litigation involving medical faculty and academic medical centers, 1950-1991.
    Helms LB; Helms CM
    Acad Med; 1993 Jan; 68(1):7-19. PubMed ID: 8447897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.